Every 10-Q that Enovis Corporation (ENOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENOV filings page.
Enovis Corporation reported higher sales and returned to operating profitability for the three and six months ended July 3, 2026. Net sales were $582,782 (Dollars in thousands) for the quarter and $1,171,933 (Dollars in thousands) year to date, up from $564,545 and $1,123,379 (Dollars in thousands) a year earlier. Operating income reached $17,413 (Dollars in thousands) for the quarter and $23,943 (Dollars in thousands) year to date, compared with operating losses in the prior periods. Higher income tax expense produced small net losses attributable to Enovis of $1,190 and $9,954 (Dollars in thousands), versus $36,739 and $92,705 (Dollars in thousands).
Prevention & Recovery revenue was broadly flat, while Reconstructive grew in both U.S. and international markets. Total Adjusted EBITDA rose to $104,321 and $207,888 (Dollars in thousands), with margins of 17.9% and 17.7%. Currency movements increased net sales by 1.0% for the quarter and 2.6% year to date. The effective tax rate exceeded 21% due to valuation allowances on U.S. deferred tax assets, non‑deductible expenses and U.S. taxation of international operations.
Operating activities generated $98,983 (Dollars in thousands) of cash in the first half, largely funding capital expenditures of $96,699 (Dollars in thousands). Cash and cash equivalents were $12,563 (Dollars in thousands), with total debt of $1,284,508 (In thousands), including a $670,559 term loan and $453,407 (In thousands) of senior unsecured convertible notes; $942 million remained available under the revolving credit facility. The company was in compliance with its credit agreement covenants and uses cross‑currency swaps and forward contracts to manage foreign exchange exposure.
Enovis Corporation reported higher sales and a much smaller loss for the three months ended April 3, 2026. Net sales rose to $589.2 million from $558.8 million, led by growth in the Reconstructive segment and modest gains in Prevention & Recovery.
Gross profit increased to $365.5 million, lifting gross margin to 62.0% from 59.4% as product mix and lower inventory step-up charges helped profitability. Net loss narrowed to $8.5 million, or $0.15 per share, compared with a $55.7 million loss a year earlier, helped by the absence of a prior one-time royalty buyout expense.
Adjusted EBITDA, a key non-GAAP metric, improved to $103.6 million from $87.1 million, with margins rising to 17.6%. Cash flow from operating activities turned positive at $24.0 million versus a slight outflow in the prior year, while the company ended the quarter with $33.1 million in cash and total debt of $1.33 billion.
Enovis (ENOV) reported Q3 2025 results with net sales of $548.9 million, up from $505.2 million a year ago, but recorded a non-cash goodwill impairment of $548.4 million. The charge drove an operating loss of $558.5 million and a net loss of $570.9 million, or $9.99 per share from continuing operations.
Both segments grew: Prevention & Recovery sales were $290.9 million and Reconstructive sales were $258.0 million. Adjusted EBITDA was $94.8 million versus $90.2 million, reflecting underlying operating performance despite elevated non-cash items.
The company approved and closed the sale of its Dr Comfort Footcare Solutions line to Promus Equity Partners for up to $60 million in cash, including $45 million upfront and up to $15 million contingent on milestones. Enovis recognized a $7.6 million loss on assets held for sale in connection with the transaction. Year-to-date, cash from operations was $128.7 million. Total debt was $1.36 billion, with $355 million available on the Revolver and a 5.75% weighted-average borrowing rate. Shares outstanding were 57.19 million as of October 31, 2025.
Enovis (ENOV) Q2 2025 10-Q highlights: Net sales grew 7.5% YoY to $564.5 million, led by Reconstructive (+10.7%) and steady Prevention & Recovery (+4.6%). Gross profit rose 15.9% to $334.7 million, lifting gross margin to 59.3% (vs. 55.0%). Operating loss narrowed to $16.8 million from $44.2 million on flat SG&A, but a $10.0 million royalty-buyout charge, higher R&D and intangible amortization kept GAAP earnings negative.
The company reported a net loss attributable to Enovis of $36.7 million (-$0.64 per share) versus $18.6 million (-$0.34) last year, driven by a $10.8 million tax expense versus an $8.9 million benefit in the prior period and hedging losses. Adjusted EBITDA improved 7.7% to $97.1 million. Operating cash flow swung to an inflow of $46.2 million (-$28.4 million LY) as working-capital efficiencies offset higher inventory. Cash ended at $44.1 million; total debt increased to $1.39 billion, lifting net debt by $84 million since year-end.
Balance-sheet expansion reflects completion of seven small acquisitions ($35 million consideration) and Lima integration costs. Inventories climbed 15% YTD, while goodwill and intangibles rose after bolt-on deals. Management remains in compliance with leverage covenants (senior secured leverage ≤3.5×) and has $325 million undrawn on its $900 million revolver.